RISPERIDONE IN TREATMENT OF AUTISM AND PERVASIVE DEVELOPMENTAL DISORDERS

$0M01FY2000RRNIH

Yale University, New Haven CT

Investigators

Linked publications & trials

Paper 37726016 Paper 32978526 Paper 31691959 Paper 30737489 Paper 30504071 Paper 29872859 Paper 29538362 Paper 28325061 Paper 28283553 Paper 28279433 Paper 27423510 Paper 27131403 Paper 27117196 Paper 26895876 Paper 26516117 Paper 26407251 Paper 26348753 Paper 26262903 Paper 26080344 Paper 25955535 Paper 25449221 Paper 25425651 Paper 25349317 Paper 25118269 Paper 24934607 Paper 24732104 Paper 24554564 Paper 24472229 Paper 24322171 Paper 24135709 Paper 23867958 Paper 23867957 Paper 23856854 Paper 23807719 Paper 23733791 Paper 23582139 Paper 23329565 Paper 23324523 Paper 23295144 Paper 23080477 Paper 22926660 Paper 22914450 Paper 22835646 Paper 22814942 Paper 22773292 Paper 22689874 Paper 22684193 Paper 22684157 Paper 22644414 Paper 22641761 Paper 22562288 Paper 22499082 Paper 22371462 Paper 22325187 Paper 22147379 Paper 22007016 Paper 21960671 Paper 21669899 Paper 21518717 Paper 21496193 Paper 21471553 Paper 21378596 Paper 21272067 Paper 21241948 Paper 21187312 Paper 21156204 Paper 21149431 Paper 21146184 Paper 21145756 Paper 21098157 Paper 20921569 Paper 20876174 Paper 20807062 Paper 20732945 Paper 20587676 Paper 20542294 Paper 20472939 Paper 20472937 Paper 20415603 Paper 20347043 Paper 20200540 Paper 20166790 Paper 20105142 Paper 20032809 Paper 20008430 Paper 20006323 Paper 19948631 Paper 19833320 Paper 19798046 Paper 19779585 Paper 19675205 Paper 19651577 Paper 19564290 Paper 19560547 Paper 19459909 Paper 19401682 Paper 19336372 Paper 19244568 Paper 19204058 Paper 19171637

Abstract

Risperidone will be evaluated for safety and efficacy in the treatment of children and adolescents with autism. This study consists of a short and a long term phase. Both phases include a period of double-blind, placebo control. Multiple measures will be made of each subject, in the control and treatment groups, throughout the course of the study.

View original record on NIH RePORTER →